SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

blonca9
Jan 14
1 min read

Catherine Owen Adams walks us through the latest on NUPLAZID and DAYBUE, and products in development for Alzheimer's psychosis, Prader-Willi, and essential tremor. Plus, the company's $700M cash balance and deal appetite.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

SF Healthcare Week: With two commercial products providing cash flow, and more in development, the new CEO of Acadia Pharma is ready to do deals

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight